OptimizeRx/$OPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About OptimizeRx
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Ticker
$OPRX
Sector
Primary listing
Employees
129
Headquarters
Website
OptimizeRx Metrics
BasicAdvanced
$328M
-
-$0.54
1.33
-
Price and volume
Market cap
$328M
Beta
1.33
52-week high
$20.70
52-week low
$3.78
Average daily volume
379K
Financial strength
Current ratio
2.568
Quick ratio
2.41
Long term debt to equity
21.349
Total debt to equity
24.291
Interest coverage (TTM)
0.61%
Profitability
EBITDA (TTM)
7.961
Gross margin (TTM)
64.39%
Net profit margin (TTM)
-9.42%
Operating margin (TTM)
3.47%
Effective tax rate (TTM)
-6.07%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
1.33%
Return on equity (TTM)
-8.21%
Valuation
Price to revenue (TTM)
3.111
Price to book
2.75
Price to tangible book (TTM)
66.64
Price to free cash flow (TTM)
32.347
Free cash flow yield (TTM)
3.09%
Free cash flow per share (TTM)
0.547
Growth
Revenue change (TTM)
25.90%
Earnings per share change (TTM)
-46.97%
3-year revenue growth (CAGR)
17.76%
10-year revenue growth (CAGR)
31.11%
3-year earnings per share growth (CAGR)
11.31%
10-year earnings per share growth (CAGR)
29.04%
What the Analysts think about OptimizeRx
Analyst ratings (Buy, Hold, Sell) for OptimizeRx stock.
Bulls say / Bears say
Q2 2025 revenue jumped 55% year-over-year to $29.2 million, driven by strong demand for OptimizeRx's digital point-of-care messaging solutions. (GlobeNewswire)
Management increased full-year 2025 revenue guidance to $104 million–$108 million and raised adjusted EBITDA guidance to $14.5 million–$17.5 million, signaling confidence in ongoing growth. (GlobeNewswire)
OptimizeRx paid down $4.5 million in principal on its term loan during Q2, highlighting strong free cash flow and a commitment to reducing leverage. (GlobeNewswire)
59% of total revenue in Q2 2025 came from the top 20 pharmaceutical manufacturer clients, highlighting the risk of customer concentration in a competitive digital health market. (GlobeNewswire)
Net revenue retention fell to 121% over the twelve months ended June 30, 2025, compared to 124% in the previous year, signaling possible challenges in upselling or customer retention. (GlobeNewswire)
GAAP net income of $1.5 million on Q2 revenue of $29.2 million reflects a slim net margin of about 5%, suggesting constrained scalability of profitability. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2025.
OptimizeRx Financial Performance
Revenues and expenses
OptimizeRx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for OptimizeRx stock?
OptimizeRx (OPRX) has a market cap of $328M as of October 08, 2025.
What is the P/E ratio for OptimizeRx stock?
The price to earnings (P/E) ratio for OptimizeRx (OPRX) stock is 0 as of October 08, 2025.
Does OptimizeRx stock pay dividends?
No, OptimizeRx (OPRX) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next OptimizeRx dividend payment date?
OptimizeRx (OPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for OptimizeRx?
OptimizeRx (OPRX) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.